top of page
Cost Of Care: Rare Diseases Expose Need To Revamp US Drug Pricing Policy
Developing more effective treatments for patients with no other options while also keeping costs down will require a balancing act with...
Incubate Coalition
Oct 19, 2021
SIGNAL WATCHING: How Life Science Venture Capital Perceives Medicare Part D Reforms
SIGNAL WATCHING: How Life Science Venture Capital Perceives Medicare Part D Reforms The 117th Congress is discussing a wide variety of...
Incubate Coalition
Sep 9, 2021
What M&A Critics Don’t Understand About Drug Innovation
We want brilliant minds at thousands of small, unheard-of biotechs chasing tomorrow’s cures. But they can only do so if larger...
Incubate Coalition
Jun 13, 2021
The Pathway To Drug Development Driven By Private Capital
Video narrated by Sara Nayeem, Avoro Ventures
Incubate Coalition
Jun 10, 2021
FINAL NIST Oral Testimony – John Stanford, Incubate
We're here today to lend our strong support to the proposed clarification of the appropriate use of "march-in" authority under Bayh Dole....
Incubate Coalition
Feb 25, 2021
Mergers And Acquisitions: A Key Driver Of VC Investment In Healthcare
The drug pricing debate is a worthy one. We have to have open discussions about maximizing innovation and access. But half-written...
Incubate Coalition
Feb 18, 2021
bottom of page